Alpha-1 antitrypsin PiMZ genotype is associated with chronic obstructive pulmonary disease in two racial groups

Annals of the American Thoracic Society

Volumn 14, Issue 8, 2017, Pages 1280-1287

  Foreman, Marilyn G ^a   Wilson, Carla ^b   DeMeo, Dawn L ^c   Hersh, Craig P ^c   Beaty, Terri H ^d   Cho, Michael H ^c   Ziniti, John ^c   Curran Everett, Douglas ^b,e   Criner, Gerard ^f   Hokanson, John E ^e   Brantly, Mark ^g   Rouhani, Farshid N ^g   Sandhaus, Robert A ^b   Crapo, James D ^b   Silverman, Edwin K ^c  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

African Americans; Alpha 1 antitrypsin deficiency; Chronic obstructive pulmonary disease; Emphysema; Genetics

Indexed keywords

ALPHA 1 ANTITRYPSIN; SERPINA1 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ALLELE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; CONE BEAM COMPUTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; SMOKING; AGED; CLINICAL TRIAL; ETHNOLOGY; GENETICS; MULTIVARIATE ANALYSIS; PHENOTYPE; RISK ASSESSMENT; STATISTICAL MODEL; UNITED STATES; VITAL CAPACITY;

AFRICAN AMERICANS; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; UNITED STATES; VITAL CAPACITY;

EID: 85026754123     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201611-838OC     Document Type: Article

References (39)

1. Silverman EK, Sandhaus RA. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360:2749-2757.
2. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency-a model for conformational diseases. N Engl J Med 2002;346:45-53.
3. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985;1:152-154.
4. Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983;77:14-27.
5. Guthery SL, Salisbury BA, Pungliya MS, Stephens JC, Bamshad M. The structure of common genetic variation in United States populations. Am J Hum Genet 2007;81:1221-1231.
6. Seersholm N. Pi MZ and COPD: will we ever know? Thorax 2004;59: 823-825.
7. Feld RD. Heterozygosity of alpha 1-antitrypsin: a health risk? Crit Rev Clin Lab Sci 1989;27:461-481.
8. Seersholm N, Wilcke JT, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha1-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000; 161:81-84.
9. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in a1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002;136:270-279.
10. Silva GE, Sherrill DL, Guerra S, Barbee RA. A longitudinal study of a1-antitrypsin phenotypes and decline in FEV1 in a community population. Chest 2003;123:1435-1440.
11. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in a1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004;59:843-849.
12. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Spirometry for health care providers. 2010 [accessed 2017 Jul 7]. Available from: http://goldcopd.org/gold-spirometry-guide/.
13. Wan ES, Castaldi PJ, Cho MH, Hokanson JE, Regan EA, Make BJ, Beaty TH, Han MK, Curtis JL, Curran-Everett D, et al.; COPDGene Investigators. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res 2014;15:89.
14. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
15. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, et al.; COPDGene Investigators. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 2011; 261:274-282.
16. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010;7:32-43.
17. Cho MH, Castaldi PJ, Hersh CP, Hobbs BD, Barr RG, Tal-Singer R, Bakke P, Gulsvik A, San José Estépar R, Van Beek EJ, et al.; NETT Genetics, ECLIPSE, and COPDGene Investigators. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. Am J Respir Crit Care Med 2015;192:559-569.
18. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168: 818-900.
19. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med 1988;84:13-31.
20. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
21. Ashraf H, Lo P, Shaker SB, de Bruijne M, Dirksen A, Tønnesen P, Dahlbäck M, Pedersen JH. Short-term effect of changes in smoking behaviour on emphysema quantification by CT. Thorax 2011; 66:55-60.
22. DeMeo DL, Silverman EK. a1-Antitrypsin deficiency. 2: genetic aspects of a1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59:259-264.
23. Sandford AJ, Weir TD, Spinelli JJ, Paré PD. Z and S mutations of the a1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 1999;20:287-291.
24. Sørheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, Agustí A, Calverley PM, Donner CF, et al. a1-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010;138:1125-1132.
25. Silva GE, Guerra S, Keim S, Barbee RA, Sherrill DL. Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ a1-antitrypsin phenotype. Chest 2008;133:1095-1100.
26. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Paré PD. Susceptibility genes for rapid decline of lung function in the Lung Health Study. Am J Respir Crit Care Med 2001;163:469-473.
27. Silverman EK. Risk of lung disease in PI MZ heterozygotes: current status and future research directions. Ann Am Thorac Soc 2016;13 (Suppl 4):S341-S345.
28. Thun GA, Ferrarotti I, Imboden M, Rochat T, Gerbase M, Kronenberg F, Bridevaux PO, Zemp E, Zorzetto M, Ottaviani S, et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. PLoS One 2012;7:e42728.
29. Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, Greene CM, O'Neill SJ, Silverman EK, McElvaney NG. Clarification of the risk of chronic obstructive pulmonary disease in a1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189:419-427.
30. Silverman EK, Province MA, Campbell EJ, Pierce JA, Rao DC. Family study of alpha 1-antitrypsin deficiency: effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits. Genet Epidemiol 1992;9:317-331.
31. Silverman EK, Province MA, Rao DC, Pierce JA, Campbell EJ. A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency: quantitative phenotypes. Am Rev Respir Dis 1990;142:1015-1021.
32. Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, Demeo DL, Sylvia JS, Ziniti J, Laird NM, et al.; NETT Genetics, ICGN, ECLIPSE and COPDGene Investigators. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir Med 2014;2:214-225.
33. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, et al.; ICGN Investigators; ECLIPSE Investigators; COPDGene Investigators. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2012;21:947-957.
34. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 2010;42:200-202.
35. Pillai SG, Ge D, ZhuG, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, et al.; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5: e1000421.
36. Wilk JB, Chen TH, Gottlieb DJ, Walter RE, Nagle MW, Brandler BJ, Myers RH, Borecki IB, Silverman EK, Weiss ST, et al. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet 2009;5:e1000429.
37. Hobbs BD, Parker MM, Chen H, Lao T, Hardin M, Qiao D, Hawrylkiewicz I, Sliwinski P, Yim JJ, Kim WJ, et al.; NETT Genetics Investigators; ECLIPSE Investigators; COPDGene Investigators; International COPD Genetics Network Investigators. Exome array analysis identifies a common variant in IL27 associated with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016;194:48-57.
38. Hogarth DK, Rachelefsky G. Screening and familial testing of patients for alpha 1-antitrypsin deficiency. Chest 2008;133:981-988.
39. Sandhaus RA, Turino G, Stocks J, Strange C, Trapnell BC, Silverman EK, Everett SE, Stoller JK; Medical and Scientific Advisory Committee of the Alpha-1 Foundation. a1-Antitrypsin augmentation therapy for PI∗MZ heterozygotes: a cautionary note. Chest 2008;134:831-834.